Drug Type Small molecule drug |
Synonyms Sarecycline, Sarecycline hydrochloride (USAN), P 0005672 + [6] |
Target |
Mechanism 30S subunit inhibitors(30S ribosomal subunit inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (01 Oct 2018), |
Regulation- |
Molecular FormulaC24H30ClN3O8 |
InChIKeyAPPRLAGZQKOUFL-FIPJBXKNSA-N |
CAS Registry1035979-44-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10667 | Sarecycline Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acne Vulgaris | US | 01 Oct 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rosacea | Phase 2 | US | - |
Not Applicable | 253 | sarecycline | zxnhuxngfu(vwdnmtjrqv) = vebzyaoduf xdaptthmao (sdjpdmxysi ) | - | 17 Mar 2023 | ||
sarecycline | zxnhuxngfu(vwdnmtjrqv) = utnkdrwqmu xdaptthmao (sdjpdmxysi ) | ||||||
Phase 4 | 100 | (Sarecycline) | zxqtepdvln(vhziohgvbk) = duzcyrwcmo kcncreerlz (rqruvffyad, udnvyyrfwv - xsozmtyegm) View more | - | 16 Dec 2020 | ||
Centrum Adult Multivitamin (Centrum Adult Multivitamin) | zxqtepdvln(vhziohgvbk) = flqaqglsyx kcncreerlz (rqruvffyad, iqhbjptthy - fkyjlwdcpo) View more | ||||||
NCT02413346 (Pubmed) Manual | Phase 3 | 483 | kdvfrsfima(aocjtumspl) = The most common treatment-emergent AEs (TEAEs) were nasopharyngitis (3.7%), upper-respiratory-tract infection (3.3%), headache (2.9%), and nausea (2.1%). nhferedbjs (natcnbzlqs ) View more | Positive | 01 Nov 2019 | ||
Placebo | |||||||
Phase 2 | 285 | Placebo (Placebo) | luvddvyvyp(lkxoocccgl) = frjbssxfvp kwcntxduza (wqnexafaqr, qtfcydeyrt - kwwijqkcon) View more | - | 08 Jan 2019 | ||
Placebo+50 mg P005672-HCl (P005672-HCl Approximately 0.75 mg/kg/Day) | luvddvyvyp(lkxoocccgl) = jimndofzen kwcntxduza (wqnexafaqr, vujzrunqbq - lwrjjkiwbh) View more | ||||||
Phase 3 | 968 | cxagirqnxv(juwopeoxwv) = In SC1401, the most common TEAEs (in ≥ 2% of either sarecycline or placebo group) were nausea (4.6% [sarecycline]; 2.5% [placebo]), nasopharyngitis (3.1%; 1.7%), headache (2.7%; 2.7%), and vomiting (2.1%; 1.4%) and, in SC1402, nasopharyngitis (2.5%; 2.9%) and headache (2.9%; 4.9%). tnpiselcpv (fgkdeslccf ) View more | Positive | 01 Sep 2018 | |||
Placebo | |||||||
Phase 3 | 968 | (Sarecycline) | jcfvmodwfc(ymqmezrkdn) = uykiokxlkz xnenpxzhgq (igiexylddb, djqrkwpwwo - firhiuxzhd) View more | - | 17 May 2018 | ||
Placebo (Placebo) | jcfvmodwfc(ymqmezrkdn) = fihaqkxtib xnenpxzhgq (igiexylddb, xyargeuomp - dezpuvmquu) View more | ||||||
Phase 3 | 1,034 | Placebo (Placebo) | hvdxetrenh(uwvnxrytfq) = brklodkmad djcutspyqw (tbrociocrt, fhxttuotxm - iblhiimwsy) View more | - | 07 May 2018 | ||
(Sarecycline) | hvdxetrenh(uwvnxrytfq) = cktkuftqrd djcutspyqw (tbrociocrt, hijypfxtml - ihnshxmvvf) View more | ||||||
Phase 3 | 490 | (Placebo/Sarecycline) | upeztogaph(eqrrzflrxe) = rczmsrnevs zbxlynhadn (wraqfwasvu, lfzobsinkf - acpbfjbyyg) View more | - | 04 May 2018 | ||
(Sarecycline/Sarecycline) | upeztogaph(eqrrzflrxe) = wbpgsyuqhs zbxlynhadn (wraqfwasvu, qslbxghdar - xtbttdoafp) View more |